novel therapeutics, translational approaches
Ph.D. M.D. FRCPC (Medical Oncology)
Queen's University University of Calgary
Department of Medicine and Oncology
Faculty of Medicine, Tom Baker Cancer Centre
Translational Laboratories, Tom Baker Cancer Centre
Director of Oncology Training Programs,
University of Calgary
Translational research involving viral oncolysis, apoptosis and graft engineering of stem cells.
Phone: (403) 521-3166
Fax: (403) 283-1651
Southern Alberta Cancer Research Institute
Oncology, Division of Medical Oncology
As a translational researcher, my interests lie in bringing novel therapeutics into the clinic. My laboratory has interests in viral oncolysis and mechanisms therein, as well as graft engineering of autologous stem cell transplant products and interests in prostate carcinoma murine model systems. Recently, we have been investigating the role of immunotherapeutics in Breast/Prostate cancers using a novel viral vaccine approach.
17119-A randomized double-blind placebo controlled study of subject with previously untreated extensive-stage small cell lung cancer with platinum plus etoposide chemotherapy
P.I. Dr. D. Morris
ET743 STS-201. A randomized phase I, multicenter, open label study of Yondelis by two different schedules in subjects with locally advanced or metastatic liposarcoma or leiomyosarcoma following treatment with anthracycline and Ifosfamide. P.I. Dr. D. Morris
GSK615. An open label, multicenter trial comparing 2 schedules of GW572016 as first line monotherapy in subjects with locally advanced or metastatic non-small cell lung cancer. P.I. Dr. D. Morris
An open label multicenter randomized phase III study comparing combination IV topotecan/docetaxel to docetaxel alone in second line advanced non-small cell lung cancer. P.I. Dr. D. Morris
20010145: A randomized , double blind, placebo controlled study of subjects with previously untreated extensive stage small cell lung cancer treated with platinum plus etoposide chemotherapy with or without darbopoetin alfa. P.I. Dr. D. Morris
A dose finding study of fixed dose vinorelbine and escalating doses ifosfamide, on days 1 and 8 in patients with advanced non-small cell lung cancer. P.I. Dr. D. Morris.
10484-A 389: an open - label, multicentre, randomized, Phase III Study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naïve patients with extensive disease-small cell lung cancer. P.I. Dr D. Morris
10464-A: an open-label, multicentre, randomized, Phase III comparator study of active symptom control alone or in combination with oral topotecan in patients with relapsed SCLC. P.I. D. Morris
A6181004: A phase III, randomized, double blind. Placebo controlled study of SU011248 in the treatment of patients with Gleevec resistant or intolerant malignant gastrointestinal stromal tumour. P.I. Dr D. Morris
A phase II, multicentre trial comparing two schedules of GW572016 as first line monotherapy in subjects with advanced or metastatic non-small cell lung cancer. P.I. Dr D Morris
CP02-0452: Randomized phase III study of docetaxel or pemetrexed with or without cetuximab in patients with recurrent or progressive non-small cell lung cancer after platinum-based therapy. P.I. Dr. D. Morris
B017704 (NSCLC): A randomized, double-blind 2-stage phase III study of bevacizumab in combination with cisplatin and Gemcitabine versus placebo, cisplatin and Gemcitabine in patients with advanced or recurrent non-squamous non-small cell lung cancer, who have not received prior chemotherapy. P.I. D. Morris
NCIC, ACB, CBCRF, CBCRA, and CPCRF.